A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).
Inclusion Criteria:
Exclusion Criteria:
Capital Federal, Buenos Aires 1426, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires 1280, Argentina
Ciudad Autonoma Buenos Aires, Distrito Federal 1118, Argentina
Macquarie University, New South Wales 2109, Australia
North York, Ontario M2K 1E1, Canada
Pierre Benite Cedax, 69495, France
Kita-gun, Kagawa-ken 761-0793, Japan
Hidaka-shi, Saitama 3501298, Japan
Hamamatasu, Shizuoka 431-3192, Japan
Minato-ku, Tokyo 1058470, Japan
Shinjuku-ku, Tokyo 160-8582, Japan
Sittard-Geleen, 6162 BG, Netherlands
Lorenskog, 1478, Norway
Gyeongsangnam-do, 50612, South Korea